Literature DB >> 21593862

Molecular mechanisms and clinical applications of angiogenesis.

Peter Carmeliet1, Rakesh K Jain.   

Abstract

Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593862      PMCID: PMC4049445          DOI: 10.1038/nature10144

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  100 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 2.  Control of cardiovascular differentiation by microRNAs.

Authors:  Kisho Ohtani; Stefanie Dimmeler
Journal:  Basic Res Cardiol       Date:  2010-12-24       Impact factor: 17.165

Review 3.  Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration.

Authors:  Beate Heissig; Chiemi Nishida; Yoshihiko Tashiro; Yayoi Sato; Makoto Ishihara; Makiko Ohki; Ismael Gritli; Jeanette Rosenkvist; Koichi Hattori
Journal:  Histol Histopathol       Date:  2010-06       Impact factor: 2.303

4.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.

Authors:  Young Jun Koh; Hak-Zoo Kim; Seong-Ik Hwang; Jeung Eun Lee; Nuri Oh; Keehoon Jung; Minah Kim; Kyung Eun Kim; Homin Kim; Nam-Kyu Lim; Choon-Ju Jeon; Gyun Min Lee; Byeong Hwa Jeon; Do-Hyun Nam; Hoon Ki Sung; Andras Nagy; Ook Joon Yoo; Gou Young Koh
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

5.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

Authors:  Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Johan R de Jong; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

Review 6.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 8.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.

Authors:  Gavin Thurston; Irene Noguera-Troise; George D Yancopoulos
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

9.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 10.  PDGF and vessel maturation.

Authors:  Carina Hellberg; Arne Ostman; C-H Heldin
Journal:  Recent Results Cancer Res       Date:  2010
View more
  1770 in total

1.  Inorganic polyphosphate induces accelerated tube formation of HUVEC endothelial cells.

Authors:  Werner E G Müller; Maximilian Ackermann; Shunfeng Wang; Meik Neufurth; Rafael Muñoz-Espí; Qingling Feng; Heinz C Schröder; Xiaohong Wang
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

Review 2.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

3.  Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity.

Authors:  SoHyun Han; Radka Stoyanova; Hansol Lee; Sean D Carlin; Jason A Koutcher; HyungJoon Cho; Ellen Ackerstaff
Journal:  Magn Reson Med       Date:  2017-07-20       Impact factor: 4.668

4.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

5.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

Review 6.  Cellular and molecular mechanisms underlying blood vessel lumen formation.

Authors:  Marta S Charpentier; Frank L Conlon
Journal:  Bioessays       Date:  2013-12-09       Impact factor: 4.345

7.  Profilin phosphorylation as a VEGFR effector in angiogenesis.

Authors:  Michael Simons; Martin A Schwartz
Journal:  Nat Cell Biol       Date:  2012-10       Impact factor: 28.824

8.  O2-controllable hydrogels for studying cellular responses to hypoxic gradients in three dimensions in vitro and in vivo.

Authors:  Daniel M Lewis; Michael R Blatchley; Kyung Min Park; Sharon Gerecht
Journal:  Nat Protoc       Date:  2017-07-20       Impact factor: 13.491

Review 9.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

10.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.